Millions afflicted with Chagas disease and other disorders of aberrant glycosylation suffer symptoms consistent with altered electrical signaling such as arrhythmias, decreased neuronal conduction velocity, and hyporeflexia. Cardiac, neuronal, and muscle electrical signaling is controlled and modulated by changes in voltage-gated ion channel activity that occur through physiological and pathological processes such as development, epilepsy, and cardiomyopathy. Glycans attached to ion channels alter channel activity through isoform-specific mechanisms. Here we show that regulated and aberrant glycosylation modulate cardiac ion channel activity and electrical signaling through a cell-specific mechanism. Data show that nearly half of 239 glycosylation-associated genes (glycogenes) were significantly differentially expressed among neonatal and adult atrial and ventricular myocytes. The N-glycan structures produced among cardiomyocyte types were markedly variable. Thus, the cardiac glycome, defined as the complete set of glycan structures produced in the heart, is remodeled. One glycogene, ST8sia2, a polysialyltransferase, is expressed only in the neonatal atrium. Cardiomyocyte electrical signaling was compared in control and ST8sia2 (؊/؊) neonatal atrial and ventricular myocytes. Action potential waveforms and gating of less sialylated voltage-gated Na ؉ channels were altered consistently in ST8sia2 (؊/؊) atrial myocytes. ST8sia2 expression had no effect on ventricular myocyte excitability. Thus, the regulated (between atrium and ventricle) and aberrant (knockout in the neonatal atrium) expression of a single glycogene was sufficient to modulate cardiomyocyte excitability. A mechanism is described by which cardiac function is controlled and modulated through physiological and pathological processes that involve regulated and aberrant glycosylation. action potentials ͉ cardiomyocyte ͉ glycomics ͉ ion channels ͉ sialic acids
T he glycome, defined as the complete set of glycan structures produced by the body, is comprised of hundreds of thousands of unique structures (1) . Such structural diversity is the result of the activity of nearly 250 known glycosylation-associated genes such as glycosyltransferases, glycosidases, and nucleotide sugar synthesis and transporter genes (glycogenes) that are responsible collectively for producing the glycans attached to lipids and proteins (2) . Functional roles for glycans in cellular communication include cell adhesion, self-recognition, protein trafficking and clearance, and receptor activation (2) .
Electrical signaling occurs in all cells of the body and is of primary importance to excitable cell function. Neurons, skeletal muscle, and cardiac muscle communicate through production and conduction of orchestrated electrical signals called action potentials (AP). Neuronal and muscle APs are transient membrane depolarizations produced by the concerted activities of many types of voltage-gated ion channels and transport proteins. Slight alterations in ion channel activity can lead to altered excitability observed as a change in AP waveform and/or conduction. For example, the types and relative densities of the set of voltage-gated K ϩ channel (K v ) isoforms expressed change as the healthy heart becomes hypertrophied and more susceptible to arrhythmias (3) . Electrical remodeling occurs during development and aging, among species, and throughout the heart (4, 5) . In nearly all cardiac pathologies including hypertrophy, heart failure, and long QT syndrome (LQTS), at least one type of remodeling occurs (3, 6) .
Voltage-gated ion channels are heavily glycosylated, with glycan structures comprising upwards of 30% of the mature channel mass (7, 8) . Previous reports indicated that the sugars attached to cardiac voltage-gated Na ϩ channels (Na v ) and K v may impact channel gating (9, 10) . Glycosylation of Na v and K v subunits were shown to alter channel gating in isoform-and subunit-dependent manners (11) (12) (13) (14) . Most studies established that the sugar-dependent gating effects were imposed by the terminal residue attached to carbohydrate structures, sialic acid. A recent work showed that variable sialic acid levels attached to a single Na v isoform, Na v 1.5, were responsible for differences in channel gating observed among neonatal and adult atrial and ventricular cardiomyocytes (15) .
There are at least two major types of disorders of aberrant glycosylation that result in decreased glycoprotein sialylation and afflict nearly 20 million people: Congenital disorders of glycosylation (CDGs; Ϸ30 known diseases) and Chagas disease, caused by parasitic infection. The primary target organ for Chagas disease and for some CDGs is the heart, leading to an increased susceptibility to conduction anomalies, cardiac arrhythmias, and heart failure (16) (17) (18) (19) . Thus, these diseases lead to aberrant cardiac glycosylation and to symptomatic changes in cardiac excitability.
Previous studies established that N-glycosylation, typically sialic acids, modulate voltage-gated ion channel gating through isoformspecific mechanisms. Individuals afflicted with certain disorders of reduced glycosylation present with arrhythmias consistent with changes in cardiac ion channel function. However, little is known about a direct role for glycans in cardiac function. Here we show that electrical communication in the heart is modulated by regulated and aberrant glycosylation. Specifically, the cardiac glycome is different in the atria than in the ventricles and the glycome is remodeled differentially during development of each cardiac chamber. Further, regulated and aberrant glycosylation modulate cardiomyocyte excitability and Na v channel function consistently.
Results
Cardiac Glycogene Expression Is Highly Regulated. To test the potential role for regulated glycosylation in cardiac excitability, our analysis began by determining whether glycogene expression levels are regulated between atria and ventricles and during cardiomyocyte development. We measured the relative expression of hundreds of glycogenes using GeneChip microarray analysis of mRNA isolated from neonatal and adult atria and ventricles (Fig. 1, Fig. S1 , and Table S1 ). Microarray data were validated using real-time RT-PCR (qPCR) analysis (Fig. S2) . The microarray and qPCR data were consistent.
The data showed that 110 of the 239 glycogenes tested were significantly differentially expressed among the four myocyte types studied (Fig. 1 A) . Each family of glycogene (glycosyltransferases, glycosidases, and sugar nucleotide synthesis/transporter genes) contributed proportionately equally to the large number of regulated glycogenes. Glycogene expression between atria and ventricles at a single developmental stage and throughout development of each chamber was also markedly regulated (Fig. 1B) .
The Cardiac Glycome Is Remodeled. To determine if the regulated expression of glycogenes translated into a remodeled cardiac glycome, neonatal and adult atrial and ventricular myocytes were subjected to glycan profiling by MALDI-TOF-MS analysis ( Fig. 2 and Table S2 ). The resultant N-glycan mass spectra are comprised of high mannose-type structures and complex-type glycans. The complex N-glycans observed comprise core fucosylated bi-, tri-, and tetra-antennary structures, which are mono-, di-, tri-, and tetrasialylated with a mixture of two forms of sialic acids, Nacetylneuraminic acid (NeuAc) and N-glycolylneuraminic acid (NeuGc).
The data indicate N-glycan structures are regulated throughout cardiomyocyte development, exemplified by the change in the relative levels of NeuAc and NeuGc attached to atrial and ventricular myocyte N-glycans. Recent studies demonstrated that MALDI-MS analyses of permethylated glycans provide reliable relative quantitative information based on signal intensities, particularly when comparisons are made over a small mass range in the same spectrum (20) . In making such comparisons, the adult Nglycan profiles exhibited a significant increase in the ratio of NeuGc to NeuAc relative to the neonatal samples (Fig. 2, inset) , indicating a change in glycan structures, particularly sialic acids, during cardiomyocyte development.
Regulated and Aberrant Sialylation Impact Cardiomyocyte Excitability. To determine whether the remodeled glycome modulates cardiac function, we observed the impact of the regulated and aberrant expression of a single glycogene on cardiomyocyte electrical activity. We studied the effect of the polysialyltransferase, ST8sia2 (responsible for addition of sialic acid polymers to N-and O-glycans), on cardiac function for several reasons that include: (i) Cardiac dysfunctions including arrhythmias and cardiomyopathy that are likely caused by changes in ion channel activity are prevalent in diseases of aberrant sialylation such as Chagas disease and some CDGs (16 -19) ; (ii) all our previous data indicated that changes in ion channel sialylation contribute significantly to the modulation of ion channel function (11) (12) (13) 15) ; and (iii) cardiac ST8sia2 expression is regulated. ST8sia2 is expressed at much higher levels in the neonatal atrium than in the neonatal ventricle as determined through microarray ( Fig. S1 A and Table S1B ) and qPCR ( Fig. S2) analyses and is essentially absent in the adult.
We questioned whether regulated and aberrant ST8sia2 expression impacted myocyte excitability by comparing cardiomyocyte AP waveform and Na v function in neonatal atrial and ventricular myocytes isolated from control and ST8sia2 knockout [ST8sia2 (Ϫ/Ϫ) ] mice ( Fig. 3 ) (21) . Several parameters of the ST8sia2 (Ϫ/Ϫ) atrial myocyte AP were significantly different compared to control data (Fig. 3) . The time to AP peak was significantly reduced in ST8sia2 (Ϫ/Ϫ) atrial myocytes while the AP duration (APD) was increased significantly. No significant differences were observed between the ST8sia2 (Ϫ/Ϫ) and control ventricular myocyte AP parameters, consistent with very low ST8sia2 expression in the ventricle.
Regulated and Aberrant Expression of a Single Glycogene Modulate
Nav Gating Consist with Observed Changes in Cardiomyocyte Excitability. To correlate AP waveform changes with a direct effect on ion channel function, whole cell Na v gating was measured in neonatal atrial and ventricular myocytes isolated from ST8sia2 (Ϫ/Ϫ) and control animals (Fig. 4) . Na v gating was not significantly different in ST8sia2 (Ϫ/Ϫ) versus control ventricular myocytes (Fig. 4 , right panels). However, there was a significant Ϸ7 mV depolarizing shift in the steady state conductancevoltage relationship measured for Na v expressed in ST8sia2
atrial myocytes compared to control data (Fig. 4A ). All other voltage-dependent gating parameters measured for the ST8sia2 (Ϫ/Ϫ) atrial Na v were shifted along the voltage axis by nearly the same magnitude and shifted toward the values measured for ventricular myocyte Na v (Fig. 4 , left panels). These data are consistent with our previous report indicating Na v sialylation impacts channel gating in the neonatal atrium but not in the neonatal ventricle (15) . These data also correlate with the AP data. First, myocyte capacitance and whole myocyte Na ϩ myocytes. Secondly, if Na v activation requires a greater depolarization (as observed in ST8sia2 (Ϫ/Ϫ) atrial myocytes), then the AP should rise more slowly (as observed in Fig. 3A ). In addition, the slower Na v inactivation rate may increase APD, although effects of ST8sia2 expression on other ion channels also responsible for setting APD may be involved.
ST8sia2 Expression Increases Level of Nav Sialylation. Immunoblot gel shift analyses were performed to question whether altered AP waveform and modulated Na v function in ST8sia2 (Ϫ/Ϫ) myocytes were caused by a direct effect of ST8sia2 expression on Na v sialylation (Tables 1 and 2 and Fig. S3 ). The data indicated that the level of Na v sialylation is greater in control atrium than in ST8sia2 (Ϫ/Ϫ) atrium, with no significant difference in sialylation levels observed between ST8sia2 (Ϫ/Ϫ) and control ventricular Na v (Table 1 and Fig. S3A ). Endoneuraminidase (EndoN) treatment, used to remove polysialic acid chains of five or more residues (22, 23) , indicated that only the control atrial Na v was polysialylated (Table 1 and Fig. S3B ). These data suggest that ST8sia2 expression and function result in increased Na v sialylation.
Discussion
Regulated and Aberrant Glycosylation Modulate Cardiomyocyte Excitability. The data indicate that ST8sia2 expression in neonatal atria is necessary for normal AP waveforms and normal Na v sialylation and gating. Because ST8sia2 expression varies between atria and ventricles, the data suggest that the regulated expression of a single glycogene modulates cardiac function. Together, the data provide an example in which regulated and aberrant glycosylation modulate cardiomyocyte excitability.
Current dogma predicts that excitability is modulated through regulated expression and redistribution of ion channel isoforms. Here, the data showed that Ͼ45% of the Ϸ250 cardiac glycogenes are significantly differentially expressed throughout the developing myocardium. Further, the data indicated that the regulated and aberrant expression of one glycogene (of Ͼ100 regulated glycogenes) was sufficient to alter cardiomyocyte AP waveforms and modulate less sialylated Na v gating consistently. This study describes a mechanism by which cardiac function can be modulated through regulated and aberrant glycosylation.
Individuals suffering from Chagas disease experience arrhythmias and conduction anomalies more frequently than those with Table S2 . (Insets) Expansions of the mass region m/z 2950 -3050 (highlighted), showing the regulated change in the relative levels of NeuAc and NeuGc sialic acids during development. Note for the two atrial samples, that the ratio of di-NeuAc to NeuAc/NeuGc to di-NeuGc determined by comparing the relative intensities of these three closely related peaks changes from Ϸ2.5:1.5:1 in the neonate to 1:1:2 in the adult sample. A similar phenomenon is observed during ventricular development and is repeated throughout the spectra. Each peak was subjected to MSMS analysis to clarify their structure. All molecular ions are present in sodiated form ([MϩNa] ϩ ).
non-chagasic dilated cardiomyopathies (17, 24) . A recent study measured mouse ECG as a function of time postinfection using two strains of Trypanosoma cruzi to infect (24) . The data indicated that Ϸ60% of infected mice (compared to Ϸ5% of control) showed some conduction abnormality. For one of the T. cruzi strains, nearly all postinfection conduction anomalies involved aberrant atrial and/or atrioventricular conduction, observed as extended P waves and PQ segments. Such ECG anomalies might be predicted with slower AP upstroke and shifted Na v voltage dependence as observed here for ST8sia2 (Ϫ/Ϫ) atrial myocytes, and are consistent with our findings for neonatal ST8sia2 (Ϫ/Ϫ) ECGs (data not shown).
How Might Regulated and Aberrant Voltage-Gated Ion Channel Glycosylation Impact Excitability? We show here that voltagedependent gating parameters measured for the less sialylated ST8sia2 (Ϫ/Ϫ) atrial Na v were shifted to more depolarized potentials compared to control Na v gating parameters (Fig. 4) . Such a shift in steady-state activation and inactivation curves would lead to depolarization of the window current, defined as the voltage range at which a small percentage of channels are persistently active. Previous reports suggest that point mutations of two Na v isoforms that cause similar shifts in window current voltage range may be responsible for such maladies as epilepsy and LQTS (25, 26) . Such changes in window current will cause a shift in the voltages at which a persistent Na ϩ current exists relative to the threshold and resting membrane potentials, and this could increase susceptibility to altered excitability.
In addition, we observed a marked reduction in the rate of recovery from fast inactivation for the ST8sia2 (Ϫ/Ϫ) atrial Na v . Previous reports suggested that faster recovery rates increase the probability of reentrant excitation, possibly resulting in LQT-3 (27) or in idiopathic ventricular fibrillation (IVF) (28) . Reentrant excitation and/or conduction block arrhythmias are prevalent in individuals suffering from Chagas disease (17) . Here we report that aberrant sialylation has a much larger impact on recovery rate than that previously implicated in IVF etiology (28) . At a Ϫ130 mV recovery potential, the less sialylated ST8sia2 (Ϫ/Ϫ) atrial Na v recovers from inactivation 30% faster than the more heavily sialylated control atrial Na v , likely increasing the susceptibility to reentrant excitation (Fig. 4G) .
Together, the data suggest that a role for regulated cardiac Na v glycosylation (sialylation) is to help control and modulate cardiac excitability and conduction achieved through a shift in the voltage dependence of Na v window current and/or a change in Na v recovery rate.
Two Mechanisms by Which Regulated Ion Channel Glycosylation Modulate Cardiac Ion Channel Function and Cardiomyocyte Excitabil-
ity. We hypothesize that two mechanisms of regulated glycosylation are responsible for modulation of voltage-gated ion channel activity: (i) Inherent differences in glycosylation (unique glycosylation signatures) among ion channel subunits and isoforms as described previously (11, 12, 29) (subunit-specific) and (ii) regulated and aberrant changes in the ability of the cardiomyocyte to glycosylate ion channel proteins as shown here (cell-specific).
With respect to the first mechanism (subunit-specific), as different isoforms or additional subunits with unique glycosylation signatures are expressed, so changes the level/location of sialic acids and other sugar residues that may contribute to channel gating. An example of this is the differential expression of Na-v ␣ subunit isoforms through skeletal muscle development. Na v 1.4 is essentially the sole Na v ␣ subunit in adult skeletal muscle, while Na v 1.5 is the dominant isoform expressed in embryonic and early postnatal muscle (30) (31) (32) . Reports indicated that Na v 1.4 is more heavily glycosylated than Na v 1.5 (11, 33) . We showed that the greater numbers of sialic acids attached to Na v 1.4 impact the voltage dependence of channel gating (11) . Thus, through a switch in isoform, muscle Na v function is altered by the varied level/location of Na v glycosylation.
We reported previously that sialic acids attached to the ␤ 1 and ␤ 2 Na v auxiliary subunits modulate Na v 1.5 gating (12, 29) . Our data show that the regulated expression of Na v 1.5 with ␤ 1 and/or ␤ 2 (or neither) can establish a sialic acid-dependent Ϸ15 mV range of channel activation voltages partially dependent on the array of glycosylation signatures created as the Na v complex is remodeled (e.g., Ϯ␤ 1 and/or Ϯ␤ 2 ).
Here we show that regulated and aberrant glycosylation modulate voltage-gated ion channel activity through changes in cardiomyocyte ion channel glycosylation, and this leads to altered cardiomyocyte excitability, supporting the second mechanism (cellspecific). The data showed that the cardiac glycome is different in the atria than in the ventricles and is remodeled differentially during development of each chamber. The regulated and aberrant expression of a single glycogene (ST8sia2) was sufficient to modulate the cardiomyocyte AP and gating of less sialylated Na v consistently.
Thus, there are two mechanisms by which regulated and aberrant glycosylation modulate cardiac excitability, a subunit-specific mechanism as described previously, and regulated changes in the cardiac glycome as described here. Both mechanisms likely occur simultaneously to produce a spectrum of possible ion channel gating mechanisms for the ion channel subunits responsible for contributing to the AP waveform. Modulation of channel function by regulated or aberrant glycosylation results in a greater level of complexity of the orchestrated activity of these ion channels, leading to altered AP waveforms, and ultimately to changes in cardiac excitability.
Regulated Glycosylation Likely Occurs Across a Spectrum of Rates. It might be inferred from our data that regulated glycosylation occurs over a developmental timeframe or at the rate of protein synthesis. However, there is evidence that both mechanisms of differential ion channel glycosylation take place on a more dynamic time scale. For example, internalized surface proteins might reenter directly into the Golgi glycosylation pathway (34) . There is also evidence that extracellular sialyltransferase and glycosidase expression is regulated and their activity may rapidly change the level of glycosylation attached to glycoproteins, resulting in a change in protein function (35) (36) (37) (38) (39) (40) . An example of this is the anti-aging protein, klotho, which has extracellular glycosidase activity (36) (37) (38) 40) . Klotho expression is highly regulated among tissues, throughout development and aging, and with pathologies such as hypertension and acute myocardial infarction [for review, see (40)]. Thus, as klotho expression is regulated, so changes klotho glycosidase activity. Klotho activity was shown to regulate surface expression of two renal epithelial ion channels, TRPV5 and ROMK1, by removing ␣2-6 sialic acids from the channels (36) (37) (38) . This desialylation leads to stabilization of channels in the plasma membrane, thereby increasing channel surface expression and ionic flux. In a second example, hippocampal network excitability is modulated by endogenous neuraminidase that removes external sialic acids (41) . If similar mechanisms are involved in cardiomyocyte function, then extracellular glycosyltransferases/glycosidases would likely produce rapid adjustments to surface channel glycosylation. Thus, the rate of modulation of ion channel gating imposed through regulated glycosylation would occur across a spectrum of rates, ranging from relatively rapid changes in surface glycan structures to the slower rate of protein synthesis to the much slower time course of development.
Summary. The data shown here indicate that the cardiac glycome is remodeled between atria and ventricles and during cardiac development. Glycogene expression is highly regulated, with Ͼ45% of glycogenes significantly differentially expressed among myocyte types. The N-glycans produced are also highly variable. The regulated and aberrant expression of a single glycogene, ST8sia2, is apparently sufficient to alter AP waveform and Na v function by changing the level of Na v sialylation. Given that expression of Ͼ100 glycogenes (including ST8sia2) are regulated throughout the developing myocardium, the potential impact of a remodeled glycome on cardiac function is profound.
Glycosylation exists in all cells and is likely regulated throughout the body, suggesting that this paradigm is relevant to control and modulation of electrical signaling in other excitable tissues. There Predicted mean molecular weight (MW) Ϯ SEM for control (ϩ/ϩ) and ST8sia2 (Ϫ/Ϫ) (Ϫ/Ϫ) atrial and ventricular Nav Ϯ EndoN treatment. Significance tested using a two-tailed t test comparing EndoN-treated samples with untreated samples. * , significant (P Ͻ 0.001); #, not significant (P Ͼ 0.3).
are diseases of aberrant sialylation such as Chagas disease and CDGs that afflict nearly 20 million people and lead to altered cardiac function consistent with the data presented here. In addition, if glycome remodeling occurs during the pathogenesis of such disorders as LQTS, heart failure, or diabetes, then the resulting aberrant glycosylation might contribute to the relative activity of cardiac glycoproteins that impact cardiac electrical signaling and thereby the symptoms associated with these disorders. Together, these data describe a mechanism by which cardiac function and likely function of other excitable tissues are controlled and modulated by regulated and aberrant glycosylation.
Materials and Methods
Please refer to the SI Text for detailed methods.
Microarray Analysis. Analysis of gene expression was conducted using a custom gene microarray (GLYCOv2 chip) produced by Affymetrix for the Consortium for Functional Glycomics (http://www.functionalglycomics.org) (42) . Hybridization and scanning of the chip were performed according to the recommended protocols (43) . Array normalization was performed using invariant set normalization available in DNA-Chip Analyzer (dChip) (www.dchip.org) software package (44, 45) . ANOVA was performed using BRB Array Tools, developed by Dr. Richard Simon and Amy Peng Lam. Heatmaps were generated with dChip program (44, 45) . The validity of the GLYCO chips was verified using qPCR (Fig. S2) . Previous reports also confirmed validity of the chips (46) . Glycomic Analysis. Myocytes isolated from neonatal and adult atria and ventricles were processed and analyzed by Core C of the Consortium for Functional Glycomics (http://www.functionalglycomics.org), as described previously (47) . N-glycans were released from extracted glycoproteins of tissue preparations by PNGase F digestion, permethylated using the sodium hydroxide procedure, and purified by Sep-Pak C18 cartridges, as previously described (47) .
Derivatized glycan samples were dissolved in methanol/water 8:2 (vol/vol) and mixed in a 1:1 ratio with 10 mg/mL 2,5-dihydroxybenzoic acid in 80:20 (vol/vol) methanol/water. A total of 0.5-to 1-L aliquots were spotted onto a target plate and dried under vacuum. MS spectra were obtained using a Voyager DE STR MALDI-TOF (Applied Biosystems) mass spectrometer in the reflectron mode with delayed extraction. Peaks observed in the MS spectra were selected for further MS/MS. MS/MS data were acquired using a 4800 MALDI TOF/TOF (Applied Biosystems) mass spectrometer.
Electrophysiology. Neonatal cardiomyocytes were isolated as described previously (15) . APs were recorded at room temperature using an Axopatch 200B amplifier (Axon Instruments) and pCLAMP software (Axon Instruments). An Ϸ700 pA supratheshold depolarizing current was injected for 1 ms from a Ϫ80 mV resting membrane potential to elicit APs. Recording solutions were described previously (9) . Na v recordings were performed as described previously (15) .
Immunoblot. Immunoblot analysis was performed on isolated atrial and ventricular myocytes as described previously (15) .
